Odonate Therapeutics Inc
OTC:ODTC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
40 000
50 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
O
|
Odonate Therapeutics Inc
OTC:ODTC
|
52.7m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
5.1B EUR |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.6B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Odonate Therapeutics Inc
Glance View
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in New York City, New York and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent. The company has completed Phase-II studies in patients with metastatic breast cancer (MBC). The firm's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).